January 22, 2018 / 1:37 PM / Updated 7 hours ago Teva's asthma treatment fails late-stage studies Reuters Staff 1 Min Read 
(Reuters) - Teva Pharmaceutical Industries said on Monday two late-stage studies testing its treatment for asthma did not meet their main goals. 
The studies were testing Tevaâ€™s subcutaneous dosing of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. 
The drug is already approved as an intravenous shot to treat patients with severe asthma. Reporting by Manas Mishra in Bengaluru; Editing by Martina D'Couto